Why the study?
Pericarditis is an uncommon and potentially life-threatening immune-related adverse event if not managed promptly.
Nivolumab can cause recurrent pericarditis, a potentially life-threatening immune-related adverse event, which may require secondary prophylaxis like colchicine if rechallenged.
Nivolumab may trigger recurrent pericarditis on rechallenge; this case report leaves open incidence, monitoring, and prophylaxis needs.
We report a case of recurrent pericarditis as an immune-related adverse event in a 47-year-old man with de novo metastatic renal cell carcinoma. After first-line treatment with sunitinib failed, he received three cycles of nivolumab and developed pericarditis following each cycle. The third cycle was accompanied by colchicine as a secondary prophylaxis. Pericarditis is an uncommon and potentially life-threatening immune-related adverse event, if not managed promptly.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: